Research graph
References from Drug delivery system targeting acid sphingomyelinase reduction in vascular endothelial and neuronal cells to restore autophagy in Alzheimer's therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Biomaterials-based anti-inflammatory treatment strategies for Alzheimer’s disease
10.4103/1673-5374.374137 · 2024 · External reference
Mammalian models in Alzheimer’s research: An update
10.3390/cells12202459 · 2023 · External reference
Amyloid-β and tau: The trigger and bullet in Alzheimer disease
10.1001/jamaneurol.2013.5847 · 2014 · External reference
Vascular and neurogenic rejuvenation in aging mice by modulation of ASM
10.1016/j.neuron.2018.09.010 · 2018 · External reference
Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: Focus on Alzheimer’s disease
10.1038/s12276-024-01176-4 · 2024 · External reference
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes
10.1007/s00401-012-1014-4 · 2012 · External reference
Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants
10.1016/j.bbrc.2010.11.115 · 2011 · External reference
Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in vivo
10.1007/s00109-023-02290-y · 2023 · External reference
Fingolimod rescues memory and improves pathological hallmarks in the 3xTg-AD model of Alzheimer’s disease
10.1007/s12035-021-02613-5 · 2022 · External reference
Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer’s disease
10.1016/j.brainres.2022.148171 · 2023 · External reference
Protein phosphatase 2A as a drug target in the treatment of cancer and Alzheimer’s disease
10.1007/s11596-020-2140-1 · 2020 · External reference
A review of autophagy mechanism of statins in the potential therapy of Alzheimer’s disease
10.31083/j.jin2102046 · 2022 · External reference
Statins as neuroprotectants: A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death
10.3233/jad-2010-101179 · 2011 · External reference
Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation
10.1177/0960327117705431 · 2018 · External reference
The role of statins in both cognitive impairment and protection against dementia: A tale of two mechanisms
10.1186/s40035-018-0110-3 · 2018 · External reference
Neuroprotective effect of Brazilin on amyloid β (25–35)-induced pathology in a human neuroblastoma model
10.1021/acsomega.0c00396 · 2020 · External reference
β-asarone prevents Aβ25-35-induced inflammatory responses and autophagy in SH-SY5Y cells: Down expression beclin-1, LC3B and up expression Bcl-2
2015 · External reference
The pathomimetic oAβ25–35 model of Alzheimer’s disease: Potential for screening of new therapeutic agents
10.1016/j.pharmthera.2023.108398 · 2023 · External reference
BACE1 inhibitors: Current status and future directions in treating Alzheimer’s disease
10.1002/med.21622 · 2020 · External reference
Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease
10.1038/s41380-023-02113-z · 2023 · External reference
Apolipoprotein serum amyloid A in Alzheimer’s disease
10.3233/jad-1999-1303 · 1999 · External reference
A reporter cell system to monitor autophagy based on p62/SQSTM1
10.4161/auto.6.6.12510 · 2010 · External reference
